Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
In the absence of other risk factors, do you treat the regional lymph nodes in triple negative breast cancer?
Or for that matter, offer PMRT on the basis of a patient having triple negative disease?
Answer from: Radiation Oncologist at Community Practice
At present I don't, but once Canadian and EORTC studies are published with full details available, it may change practice patterns.
Sign In
or
Register
to read more
415
Related Questions
Does a high genomic risk score impact your radiation fields for patients with breast cancer?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
What are your top takeaways in Breast Cancer from ESMO 2025?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Would you offer prone APBI with IMRT/VMAT?
Would you consider RNI alone without CW for an isolated nodal recurrence after treatment with mastectomy and SNB for an early-stage breast cancer with no prior RT?
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Would you consider APBI in a patient who meets all criteria but has high-risk genomic testing and is not receiving chemotherapy?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?